

**The notice contains important information that requires your immediate attention.
Should you have any query about this notice, please seek independent professional advice.**

January 17, 2024

**To Policyowners of Manulife Investment Plus 2
(the “Plan”)**

Various Changes of the Underlying Funds

We would like to notify you of the following changes with regard to the following underlying funds (each an “**Underlying Fund**” and collectively, the “**Underlying Funds**”) corresponding to the following investment choices under the Plan, following our receipt of the respective notices of the Underlying Funds.

Name of Investment Choice	Name of Underlying Fund		Share Class of Underlying Fund
JPMorgan Asia Pacific Income Fund (dist)	JPMorgan Funds – Asia Pacific Income Fund	each a “ JPMorgan Underlying Fund ” and collectively, the “ JPMorgan Underlying Funds ”	Class A (mth) – USD
JPMorgan Emerging Markets Opportunities Fund	JPMorgan Funds – Emerging Markets Opportunities Fund		Class A (acc) USD
JPMorgan Income Fund (dist)	JPMorgan Funds – Income Fund		Class A (mth) – USD
Franklin Biotechnology Discovery Fund	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund	each a “ Templeton Underlying Fund ” and collectively, the “ Templeton Underlying Funds ”	Class A Acc (USD)
Franklin Income Fund (dist)	Franklin Templeton Investment Funds – Franklin Income Fund		Class A (Mdis) USD
Franklin U.S. Opportunities Fund	Franklin Templeton Investment Funds – Franklin U.S. Opportunities Fund		Class A Acc USD
Templeton Frontier Markets Fund	Franklin Templeton Investment Funds – Templeton Frontier Markets Fund		Class A (acc)
Templeton Global Bond Fund	Franklin Templeton Investment Funds – Templeton Global Bond Fund		Class A (acc) USD
Templeton Global Total Return Fund (dist)	Franklin Templeton Investment Funds – Templeton Global Total Return Fund		Class A (Mdis) USD

1. Changes to the JPMorgan Underlying Funds

According to the notice from JPMorgan Funds (SICAV Range) (the JPMorgan Underlying Funds being sub-funds of which) dated January 11, 2024, the following changes have been made to the JPMorgan Underlying Funds.

a) Amendment to the investment policy of JPMorgan Funds – Asia Pacific Income Fund

The investment policy of JPMorgan Underlying Fund has been amended to allow investment up to 20% (previously 10%) of assets in onshore securities issued within the People’s Republic of China (“**PRC**”) including China A-Shares through the China-Hong Kong Stock Connect Programmes and onshore debt securities issued within the PRC through China-Hong Kong Bond Connect.

This amendment will not materially affect the risk profile of the JPMorgan Underlying Fund. Please refer to the Hong Kong offering documents of the JPMorgan Underlying Fund for details of the risks associated with PRC securities.

b) General updates

The Hong Kong offering documents of the JPMorgan Underlying Funds have been updated to reflect other general updates.

The Hong Kong offering documents of the JPMorgan Underlying Funds and the product key facts statements of the JPMorgan Underlying Funds have been revised to reflect the above updates.

2. Changes to the Templeton Underlying Funds

According to the notice from Franklin Templeton Investment Funds (the Templeton Underlying Funds being sub-funds of which) dated December 28, 2023, unless otherwise specified, the following changes have been made to the Templeton Underlying Funds with effect from August 27, 2023.

- a) *Updated pre-contractual disclosures of the Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund, Franklin Templeton Investment Funds – Franklin U.S. Opportunities Fund and Franklin Templeton Investment Funds - Templeton Global Bond Fund*

The pre-contractual disclosures of the Templeton Underlying Funds shall be updated to reflect the latest template required to be used pursuant to the Commission Delegated Regulation (EU) 2023/363, which includes two additional questions in relation to investment by the Templeton Underlying Funds in fossil gas and/or nuclear energy related to activities that comply with the Taxonomy Regulation¹.

In addition, the pre-contractual disclosures of the Templeton Underlying Funds shall be amended to reflect the following key updates:

- (i) The question headed “What investment strategy does this financial product follow?” in the pre-contractual disclosure of the Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund shall be revised to include “nuclear weapons” as one of the specific environmental, social, or governance (“ESG”) exclusions.

- b) *Updates to the valuation policy of Franklin Templeton Investment Funds*

To clarify that the costs incurred in obtaining and maintaining registrations in different countries as well as fees for facilities services and company secretary services are charged to Franklin Templeton Investment Funds, item (e) under the paragraph relating to total liabilities in the sub-section headed “VALUATION” in the section headed “ADDITIONAL INFORMATION” of the Explanatory Memorandum of the Templeton Underlying Funds shall be updated as follows (with revisions in mark-up):

“(e) all other liabilities of the Company of whatsoever kind and nature except liabilities represented by Shares in the Company. In determining the amount of such liabilities the Company shall take into account all relevant expenses payable by the Company comprising formation expenses, fees and expenses at the accounts, fees payable to the Management Company for the performance of its various services and for those rendered by the Investment Managers and/or investment advisers, the Depositary and local paying agents and permanent representatives in places of registration as well as costs incurred in obtaining and maintaining registrations in different countries, any other agent employed by the Company, fees for facilities services, fees for company secretary services, fees for legal and auditing services, insurance premiums, printing, reporting and publishing expenses, including the cost of advertising and/or preparing and printing of the prospectuses, product key facts statements, explanatory memoranda or registration statements, investment research fees, taxes or governmental or supervisory charges, all other operating expenses, including the cost of buying and selling assets, interest, bank charges and brokerage commissions, postage, telephone, telex, telefax message and facsimile (or other similar means of communication). The Company and/or the Administrative Agent, as appropriate, may calculate administrative and other expenses of a regular or recurring nature on an estimated figure for yearly or other periods in advance, and may accrue the same in equal proportions over any such period.”

- c) *Other updates*

The Explanatory Memorandum of the Templeton Underlying Funds shall be updated to reflect the below:

- (i) The third paragraph under the sub-section headed “ANTI-MONEY LAUNDERING AND COUNTER-TERRORIST FINANCING LEGISLATION” in the section headed “ADDITIONAL INFORMATION” shall be amended as follows (with revisions in mark-up):

“The Management Company reserves the right to ask at any time for additional information and documentary evidence, such as updated identity documentation, source of funds and origin of wealth, as may be required in higher risk scenarios or to comply with any applicable laws and regulations, including applicable Luxembourg regulations on the prevention of the use of the financial sector for money laundering purposes. In case of delay or failure to provide such information and/or documentary evidence, the Management Company may delay or reject the processing of purchase or sale instructions, or any other transaction. The Management Company may also delay or suspend the payment of dividends until relevant and satisfactory information and/or documentation is received. In addition, the Management Company reserves the right to stop the payment of any commissions and/or ultimately terminate the business relationship with sub-distributors, intermediaries, brokers/dealers and/or professional investors after reasonable attempts from the Management Company to obtain the missing or updated documentation requested from such sub-distributors, intermediaries, brokers/dealers and/or professional investors in line with applicable laws and regulations, thus preventing the Management Company from fulfilling its anti-money laundering and counter-terrorism financing obligations. Neither the Company nor the Management Company have any liability for delays or failure to process deals as a result of the Investor providing no or only incomplete information and/or documentary evidence.”

- (ii) Update to the conducting officers of the management company of the Templeton Underlying Funds; and

¹ Taxonomy Regulation refers to Regulation (EU) 2020/852 of the European Parliament and of the Council of 18 June 2020 on the establishment of a framework to facilitate sustainable investment, and amending Regulation (EU) 2019/2088, as may be amended from time to time.

(iii) Other miscellaneous, administrative and/or clarificatory updates.

The changes set out above do not amount to a material change to the Templeton Underlying Funds. There is no material change or increase in the overall risk profiles of any of the Templeton Underlying Funds following the above changes. Further, the above changes do not have a material adverse impact on rights or interests of the investors of the Templeton Underlying Funds (including changes that may limit Investors' ability in exercising their rights), and the above changes are not expected to give rise to any change in the fee level or fee structure of any of the Templeton Underlying Funds.

Any costs and/or expenses incurred in connection with the above changes shall be borne by the management company of the Templeton Underlying Funds, other than the cost of publishing the notice from Franklin Templeton Investment Funds dated December 28, 2023, which is estimated to be approximately HKD120,000 and which shall be charged and allocated to the sub-funds of Franklin Templeton Investment Funds based on the pro rata share of the net asset value of the sub-funds of Franklin Templeton Investment Funds.

Please refer to the respective notices and latest offering documents of the Underlying Funds for further information relating to the above changes.

If you have any enquiry, please do not hesitate to contact your Manulife Insurance Advisor or call our Customer Service Hotline at (852) 2108 1110 during office hours: 9:00am - 6:00pm, Monday to Friday.

Customer Services

Individual Financial Products

Manulife (International) Limited

Incorporated in Bermuda with limited liability